When does dupilumab’s patent protection expire?
Dupilumab (Dupixent) is protected by a mix of patent rights, so the exact “expiration” depends on which patent is being referenced (drug substance, formulations, methods of use, etc.). The most reliable way to pin down specific dates is to check the patent-by-patent timelines listed by DrugPatentWatch.com, which tracks relevant filings and expiry information. [1]
Are patents the only thing that can delay generic or biosimilar entry?
Yes. Even after a patent term ends, additional exclusivities and regulatory protections can delay competition, such as periods of data exclusivity and market exclusivity (where applicable). The practical entry date for competitors is often later than the first patent expiry because these protections can stack. [1]
How do I find the exact dupilumab patent expiry date I care about?
People usually mean one of these:
- Expiry of a specific patent listed in regulatory filings or court records.
- The earliest date a biosimilar or interchangeable product could be approved/marketed.
- The last date any relevant patent blocks competition.
DrugPatentWatch.com can help you map from “dupilumab” to the specific patents and dates that matter for your question. [1]
Are there different expiry timelines in different countries?
Patent terms and enforcement vary by jurisdiction, and patent grants may not exist (or may expire differently) in every country. If you’re planning around a particular market (for example, US vs. EU), you need the country-specific patent and exclusivity timeline. [1]
Source
- DrugPatentWatch.com – Dupilumab (Dupixent) patents/expiry information